08Sep
08Sep
Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer
Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its senior leadership team. Biren Amin, M.S., M.B.A. has joined the company as its Chief Financial and Strategy Officer. Mr. Amin comes to Pyramid Biosciences from Immuneering Corporation (NASDAQ: IMRX), where he previously served as the company’s Chief Financial Officer (CFO). “We are delighted Biren has joined our leadership team, particularly at this time of significant...
08Sep
Aircuity Further Enhances Analytics Platform
Aircuity, a leader in creating healthy and sustainable buildings, has introduced an enhanced version of its data analytics platform, MyAircuity. These new features both enhance security and add further depth to Aircuity’s suite of analytic insights that help clients achieve their goals of real carbon reduction and healthier indoor air quality (IAQ). “We are continuously soliciting customer feedback to drive our innovation roadmap,” said Luca Mazzei, Chief Growth Officer, Aircuity. “We continue to see opportunities to enhance the value our...
03Sep
Vision-enhancing eyewear soon to be readily available at VA hospitals
New eyewear fitted with a camera that can help low-vision people see — known as eSight devices — will be much more readily available at Veterans Affairs hospitals thanks to a partnership with veteran-owned medical supplies company Marathon Medical. Retired Army Maj. Gen. Gale Pollock, the former acting surgeon general of the Army and an advocate for people with low vision, said eSight is “truly looking to improve the lives of the men and women and the boys and girls...
02Sep
Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials
Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of MPS I. The open IND enables Immusoft to initiate a Phase 1 clinical study. This milestone is both significant for Immusoft and historic in the field of cell and gene therapies, as ISP-001 will be the first engineered B...
01Sep